Skip to main content
SpringerLink
Log in

Neuroendocrine Tumors (MIBG)

  • Chapter
Book cover Clinical Nuclear Medicine

  • 2550 Accesses

Abstract

Uptake of radiopharmaceuticals in the adrenal medulla was first demonstrated in 1967, using C-14-labeled epinephrine and precursors (Morales et al. 1967). In subsequent years this tracer was shown to depict neuroblastomas and pheochromocytomas (Lieberman et al. 1969; Anderson et al. 1973). In 1976 an iodinated compound of dopamine and a year later a radioiodinated bretylium analog were introduced (Ice et al. 1975; Korn et al. 1977). In 1980 the concentration of I-131-iodo-benzylguanidine in the adrenal medulla was reported (Wieland et al. 1980).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anderson BG, Beierwaltes WH, Harrison TS, Ansari AN, Buswink AA, Ice RD (1973) Labeled dopamine concentration in pheochromocytomas. J Nucl Med 14:781–784

    PubMed  CAS  Google Scholar 

  • Babich JW, Graham W, Fischman AJ (1997) Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells. Eur J Nucl Med 24:538–543

    PubMed  CAS  Google Scholar 

  • Beierwaltes WH (1991) Endocrine imaging: parathyroid, adrenal cortex and medulla, and other endocrine tumors. Part II. J Nucl Med 32:1627–1639

    PubMed  CAS  Google Scholar 

  • Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelmans L, Reske SN (2003) 1311/1231-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30:132–139

    Article  CAS  Google Scholar 

  • Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C (1994) Refining interpretation of MIBG scans in children. J Nucl Med 35:803–810

    PubMed  CAS  Google Scholar 

  • Brans B, Monsieurs M, Laureys G, Kaufman JM, Thierens H, Dierckx RA (2002) Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking. Med Pediatr Oncol 38: 41–46

    Article  PubMed  Google Scholar 

  • Brink I, Hoegerle S, Klisch J, Bley TA (2005) Imaging of pheochromocytoma and paraganglioma. Fam Cancer 4:61–68

    Article  PubMed  CAS  Google Scholar 

  • Britton KE (1997) Positive MIBG scanning at the time of relapse in neuroblastoma which was MIBG negative at diagnosis. Br J Radiol 70:969. Comment in: Schwarz et al. (1997) Br J Radiol 70:90–92

    PubMed  CAS  Google Scholar 

  • Carrel F, Amstutz H, Novak-Hofer I, Schubiger PA (1997) Evaluation of radioiodinated and radiocopper labeled monovalent fragments of monoclonal antibody chCE7 for targeting of neuroblastoma. Nucl Med Biol 24:539–546

    Article  PubMed  CAS  Google Scholar 

  • Castagnoli A, Biti G, De Cristofaro MT, Ferri P, Magrini SM, Papi MG, Bianchi S (1992) Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan. Eur J Nucl Med 19:913–916

    Article  PubMed  CAS  Google Scholar 

  • Castellani MR, Chiti A, Seregni E, Bombardieri E (2000) Role of 1311-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 44:77–87

    PubMed  CAS  Google Scholar 

  • Clarke SE, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP–an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33–38

    PubMed  CAS  Google Scholar 

  • Claudiani F, Stimamigliio P, Bertolazzi L, Cabria M, Conte M, Villavecchia GP, Garaventa A, Lanino E, De Bernardi B, Scopinaro G (1995) Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q J Nucl Med 39:21–24

    PubMed  CAS  Google Scholar 

  • Clerico A, Jenkner A, Castello MA, Ciofetta G, Lucarelli C, Codini M (1991) Functionally active ganglioneuroma with increased plasma and urinary catecholamines and positive iodine 131-meta-iodobenzylguanidine scintigraphy. Med Pediatr Oncol 19:329–333

    Article  PubMed  CAS  Google Scholar 

  • Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Körber C, Grünwald F (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676

    Article  PubMed  CAS  Google Scholar 

  • Diehl M, Fußhoeller G, Menzel C, Kranert WT, Graichen S, Klingebiel Th, Grünwald F (2004) Hyperbarer Sauerstoff zur Intensivierung der 1311-MIBG-Therapie beim therapierefraktären Neuroblastom Stadium 4 (case repeort). Nuklearmedizin 43:N77–N80

    Google Scholar 

  • Feldman JM, Blinder RA, Lucas KJ, Coleman RE (1986) Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors. J Nucl Med 27:1691–1696

    PubMed  CAS  Google Scholar 

  • Flower MA, Fielding SL (1996) Radiation dosimetry for 131I-mlBG therapy of neuroblastoma. Phys Med Biol 41:1933–1940

    Article  PubMed  CAS  Google Scholar 

  • Flux GD, Guy MJ, Papavasileiou P, South C, Chittenden SJ, Flower MA, Meiler ST (2003) Absorbed dose ratios for repeated therapy of neuroblastoma with 1-131 mlBG. Cancer Biother Radiopharm 18:81–87

    Article  PubMed  CAS  Google Scholar 

  • Franceschini R, Pecorale A, Chinol M, Calcagni ML, Servidei T, Riccardi R, Troncone L (1995) In vitro and in vivo studies with no-carrier added radioiodinated MIBG. Q J Nucl Med 39:72–77

    PubMed  CAS  Google Scholar 

  • Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C, Lanino E, Bertolazzi L, Villavecchia GP, Cabria M, Scopinaro G, Claudiano F, De Bernardi B (1999) I-131-metaiodobenzyl-gunaidine (I-1313-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 81:1378–1384

    Article  PubMed  CAS  Google Scholar 

  • Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST (2005) Feasibility of dosimetry-based high-dose 1311-metaiodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20:195–199

    Article  PubMed  CAS  Google Scholar 

  • Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ (1994) Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 35:1753–1757

    PubMed  CAS  Google Scholar 

  • Geoerger B, Hero B, Harms D, Grebe J, Scheidhauer K, Berthold F (2001) Metabolic activity and clinical features of primary ganglioneuromas. Cancer 91:1905–1913

    Article  PubMed  CAS  Google Scholar 

  • Hoefnagel CA (1999) Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 43:336–343

    PubMed  CAS  Google Scholar 

  • Hoefnagel CA, Schornagel J, Valdes Olmos RA (1991) [131I]metaiodobenzylguanidine therapy for malignant phaeochromocytoma: interference of medication. J Nucl Biol Med 35:308–312

    PubMed  CAS  Google Scholar 

  • Ice RD, Wieland DM, Beirwaltes WH, Lawton RG, Redmond MJ (1975) Concentration of dopamine analogs in the adrenal medulla. J Nucl Med 16:1147–1151

    PubMed  CAS  Google Scholar 

  • Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC (1989) Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30:481–489

    PubMed  CAS  Google Scholar 

  • Klingebiel T, Reuland P, Feine U, Niethammer D (1992) Verlaufsbeurteilung des metastasierten Neuroblastoms mittels hochdosiertem [131J-meta]Jodobenzylguanidin. Nuklearmedizin 31:209–212

    PubMed  CAS  Google Scholar 

  • Klingebiel T, Bader P, Bares R, Beck J, Jürgens H, Lang P, Niethammer D, Rath B, Handgretinger R (1998) Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 34:1398–1402

    Article  PubMed  CAS  Google Scholar 

  • Kohnert K, Lerch H, Thelen M, Jürgens H, Schober O (1997) Recurrence of a stage IV neuroblastoma. Nuklearmedizin 36:32–35

    PubMed  CAS  Google Scholar 

  • Korn N, Buswink A, Yu T, Carr EA Jr, Carroll M, Counsell RE (1977) A radioiodinated bretylium analog as a potential agent for scanning the adrenal medulla. J Nucl Med 18: 87–89

    PubMed  CAS  Google Scholar 

  • Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19:3397–3405

    PubMed  CAS  Google Scholar 

  • Lieberman LM, Beierwaltes WH, Varma VM, Weinhold P, Ling R (1969) Labeled dopamine concentration in human adrenal medulla and in neuroblastoma. J Nucl Med 10:93–97

    PubMed  CAS  Google Scholar 

  • Mastrangelo R, Tornesello A, Riccardi R, Lasorella A, Mastrangelo S, Mancini A, Rufini V, Troncone L (1995) A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 31 A:606–611

    Article  Google Scholar 

  • Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B (2001) Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 42:1713–1721

    PubMed  CAS  Google Scholar 

  • Maurea S, Klain M, Caraco C, Ziviello M, Salvatore M (2002) Diagnostic accuracy of radionuclide imaging using 1311 nor-cholesterol or meta-iodobenzylguanidine in patients with hypersecreting or non-hypersecreting adrenal tumours. Nucl Med Commun 23:951–960

    Article  PubMed  CAS  Google Scholar 

  • McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM (1985) Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 15:132–153

    Article  PubMed  CAS  Google Scholar 

  • Menzel C, Graichen S, Berner U, Risse JH, Diehl M, Dobert N, Hamscho N, Grunwald F (2003) Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET. Acta Med Austriaca 30:37–40

    Article  PubMed  CAS  Google Scholar 

  • Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H (2002) Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging 29:1581–1587

    Article  PubMed  CAS  Google Scholar 

  • Morales JO, Beierwaltes WH, Counsell RE, Meier DH (1967) The concentration of radioactivity from labeled epinephrine and its precursors in the dog adrenal medulla. J Nucl Med 8:800–809

    PubMed  CAS  Google Scholar 

  • Mozley PD, Kim CK, Mohsin J, Jatlow A, Gosfield E 3rd, Alavi A (1994) The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma. J Nucl Med 35:1138–1144

    PubMed  CAS  Google Scholar 

  • Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, Beierwaltes WH (1983) The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (1-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 24:672–682

    PubMed  CAS  Google Scholar 

  • Nakatani T, Hayama T, Uchida J, Nakamura K, Takemoto Y, Sugimura K (2002) Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncol Rep 9:1225–1227

    PubMed  Google Scholar 

  • Nocaudie-Calzada M, Huglo D, Carnaille B, Proye C, Marchandise X (1996) Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours. Eur J Nucl Med 23:1448–1454

    Article  PubMed  CAS  Google Scholar 

  • Oberg K, Eriksson B (2005) Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 19:265–276

    Article  PubMed  Google Scholar 

  • Piepsz A, Hahn K, Roca I, Ciofetta G, Toth G, Gordon I, Kolinska J, Gwidlet J (1990) A radiopharmaceutical schedule for imaging in paediatrics. Paediatric Task Group European Association Nuclear Medicine. Eur J Nucl Med 17:127–129

    Article  PubMed  CAS  Google Scholar 

  • Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA (2003) High-dose I-131-metaiodobenzylguanidine therapy for 12 patients with malignant phaeochromocytoma. Am Cancer Soc 98:239–248

    CAS  Google Scholar 

  • Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B (1996) Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 37:1464–1468

    PubMed  CAS  Google Scholar 

  • Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, Tyler DS, Olson JA Jr (2002) Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 101:1987–1993

    Article  CAS  Google Scholar 

  • Sari O, Ugur O, Emir S, Akyuz C (2001) Combined use of chemotherapy and 1311-metaiodobenzylguanidine in the treatment of advanced-stage neuroblastoma. Turk J Pediatr 43:29–33

    PubMed  CAS  Google Scholar 

  • Shapiro B, Gross MD (1987) Radiochemistry, biochemistry, andkinetics of 1311-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 15:170–177

    Article  PubMed  CAS  Google Scholar 

  • Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC (1999) Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET Radiology 212:35–41

    CAS  Google Scholar 

  • Sywak MS, Pasieka JL, McEwan A, Kline G, Rorstad O (2004) 1311-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid. Tumors World J Surg 28:1157–1162

    Article  Google Scholar 

  • Tobes MC, Jaques S Jr, Wieland DM, Sisson JC (1985) Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 26:897–907

    PubMed  CAS  Google Scholar 

  • Tosaka A, Ando M, Arisawa C, Okano T (1999) Endocrinologically active retroperitoneal ganglioneuroma with positive iodine-131-metaiodobenzylguanidine scintigraphy. Int J Urol 6:471–474

    Article  PubMed  CAS  Google Scholar 

  • Troncone L, Rufini V, De Rosa G, Testa A (1989) Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma. Henry Ford Hosp Med J 37:178–184

    PubMed  CAS  Google Scholar 

  • Vaidyanathan G, Welsh PC, Vitorello KC, Snyder S, Friedman HS, Zalutsky MR (2004) A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. Eur J Nucl Med Mol Imaging 31:1362–1370

    Article  PubMed  CAS  Google Scholar 

  • van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T (2002) High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 94:2081–2089

    Article  PubMed  CAS  Google Scholar 

  • van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T (2003) Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer 98:389–396

    Article  PubMed  CAS  Google Scholar 

  • Velchik MG, Alavi A, Kressel HY, Engelman K (1989) Localization of pheochromocytoma: MIBG [correction of MIGB], CT, and MRI correlation. J Nucl Med 30:328–336

    PubMed  CAS  Google Scholar 

  • Verga U, Muratori F, Di Sacco G, Banfi F, Libroia A (1989) The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma. Henry Ford Hosp Med J 37:175–177

    PubMed  CAS  Google Scholar 

  • Voûte PA, van der Kleij AJ, De Kraker J, Hoefnagel CA, Thiel van Buul MMC, Van Gennip H (1995) Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 31:596–600

    Article  Google Scholar 

  • Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH (1994) Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 21:545–559

    Article  PubMed  CAS  Google Scholar 

  • Warren MJ, Shepstone BJ, Soper N (1989) Iodine-131 meta-iodobenzylguanidine (131I-MIBG) for the localization of suspected phaeochromocytoma. Nucl Med Commun 10:467–475

    Article  PubMed  CAS  Google Scholar 

  • Watanabe N, Shimizu M, Kageyama M, Kitagawa K, Hayasaka S, Seto H (1998) 123I-MIBG SPECT of Merkel cell carcinoma. Br J Radiol 71:886–887

    PubMed  CAS  Google Scholar 

  • Wieland DM, Wu J, Brown E, Mangner TJ, Swanson DP, Beierwaltes WH (1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 21:349–353

    PubMed  CAS  Google Scholar 

  • Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JL, Hutchinson RJ (2002) Pilot studyof iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:2142–2149

    Article  PubMed  CAS  Google Scholar 

  • Zagar I, Han R, Mitrovic S (1995) Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors. Q J Nucl Med 39:13–16

    PubMed  CAS  Google Scholar 

  • Zaplatnikov K, Menzel C, Dobert N, Hamscho N, Kranert WT, Gotthard M, Behr TM, Grünwald F (2004) Case report: drug interference with MIBG uptake in a patient with metastatic paraganglioma. Br J Radiol 77:525–527

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University of Frankfurt/Main, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    M. Welsch Dr. med.

  2. Klinik für Nuklearmedizin Zentrum der Radiologie, Klinikum der J.-W.-Goethe-Universität, Theodor-Stern-Kai 7; Haus 21D, 60590, Frankfurt/Main, Germany

    F. Grünwald (Prof. Dr. med.)

Authors
  1. M. Welsch Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Grünwald
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Straße 15, D-53127, Bonn, Germany

    Hans-Jürgen Biersack M.D. (Professor and Chairman) (Professor and Chairman)

  2. Nuclear Medicine and Radiology, Albert Einstein College of Medicine Director, Dept. of Nuclear Medicine Montefiore Medical Centre/Moses Division, 111 East 210th Street, Bronx, NY, 10467, USA

    Leonard M. Freeman M.D. (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Welsch, M., Grünwald, F. (2007). Neuroendocrine Tumors (MIBG). In: Biersack, HJ., Freeman, L.M. (eds) Clinical Nuclear Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28026-2_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28026-2_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28025-5

  • Online ISBN: 978-3-540-28026-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation